Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

The pneumococcal conjugate vaccine – codenamed PCV21/GBP410 ... slightly down on the same period of 2023. MSD (known as Merck & Co in the US and Canada), meanwhile, recorded $647 million ...

Ursinus College has received a $4 million pledge that when realized will be among the largest gifts ever to the 156-year-old ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

Prior to COVID-19, pneumococcal vaccines were the largest vaccine market worldwide – estimated at around $8 billion – with Prevnar capturing almost $6 billion of that total in 2020 from its ...

Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...